---  
layout: startup_page  
title: "Avenzo Therapeutics"  
id: "avenzotx.com"  
permalink: "/avenzotherapeuticsavenzotx.com11182024/"  
website: "http://www.avenzotx.com/"  
funding_round: "Series A1"  
funding_amount: "$386M"  
investors: "OrbiMed, Foresite Capital, SR One, Lilly Asia Ventures, Surveyor Capital, New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital, three new investors"  
about: "Avenzo Therapeutics is a clinical-stage biotechnology company developing next-generation oncology therapies. Their lead drug candidate, AVZO-021, is a CDK2 inhibitor currently in Phase 1 trials for advanced solid tumors and combinations in HR+/HER2-negative metastatic breast cancer. The company also has an exclusive option agreement for a potential first-in-class Nectin4/TROP2 bispecific antibody-drug conjugate."  
markets: "Oncology, Biotechnology"  
hq: "San Diego, California, United States"  
founded_year: "2022"  
linkedin: "https://www.linkedin.com/company/avenzotx"  
twitter: ""  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/avenzo-therapeutics"  
pitchbook: "https://pitchbook.com/profiles/company/515541-25"  

date_display: "18-Nov-2024"  
date: "2024-11-18"

# SEO Optimization  
meta_title: "Avenzo Therapeutics - Series A1 Funding ($386M)"  
meta_description: "Avenzo Therapeutics, Avenzo Therapeutics is a clinical-stage biotechnology company developing next-generation oncology therapies. Their lead drug candidate, AVZO-021, is a..."  
meta_keywords: "Avenzo Therapeutics, Oncology, Biotechnology, Series A1 funding"  
canonical_url: "https://startup.projectstartups.com/avenzotherapeuticsavenzotx.com11182024/"  
---